Physician profile
Thomas Ward
NPI 1760448724
$1,059.93
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.31 · 2022: $270 · 2023: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $761.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $330.80 | 2023 | Dovato, Cabenuva |
| Gilead Sciences, INC. | $182.76 | 2022-2023 | Biktarvy |
| Abbvie INC. | $130.88 | 2022-2023 | Vraylar |
| Corium, LLC | $50.58 | 2022 | |
| Axsome Therapeutics, INC. | $44.60 | 2023 | Auvelity |
| Lundbeck LLC | $42.30 | 2022-2023 | Rexulti |
| Supernus Pharmaceuticals, INC. | $40.47 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $36.02 | 2023 | Farxiga |
| Sanofi Pasteur INC. | $28.31 | 2021 | |
| Janssen Pharmaceuticals, INC | $26.23 | 2023 | Spravato |
| Novartis Pharmaceuticals Corporation | $24.68 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $20.46 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.90 | 2023 | Austedo |
| Janssen Biotech, INC. | $18.83 | 2022 | |
| Theratechnologies INC. | $18.80 | 2023 | Trogarzo, Egrifta |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $17.41 | 2022 | |
| Novo Nordisk INC | $14.71 | 2022 | |
| Esperion Therapeutics, INC. | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.